Although isocitrate dehydrogenase mutations are specific to gliomas, proteins called neo-epitopes are produced due to these mutations, and these proteins are the target of vaccines.
Brain cancer vaccine successfully passed Phase 1 trials
Although isocitrate dehydrogenase mutations are specific to gliomas, proteins called neo-epitopes are produced due to these mutations, and these proteins are the target of vaccines.